Pacific Edge opens $5m share purchase plan

Cancer diagnostics company, Pacific Edge, has announced the opening of its $5 million share purchase plan (SPP).

The SPP is part of a larger capital raising initiative, which includes a successful conditional placement of $16.1m.

The company said the placement, which was $1.1m more than initially sought, is still subject to shareholder approval.

The new shares issued under the SPP and placement are expected to be allotted on August 13, 2025.

Eligible shareholders, who are holders of Pacific Edge shares with an address in New Zealand, can apply for up to $50,000 of new shares at a price of $0.10 per share.

The company said it plans to use the new capital to extend its cash runway, accelerate the adoption of its Triage product in the US, generate clinical evidence, and invest in innovation and product development.